Table 4.
Summary of Efficacy Results
| MTC (n = 8) | ATC (n = 10) | |
|---|---|---|
| Median PFS, months [CI] | NE [5.6−NE] | 2.8 [0.7−5.6] |
| Median OS, months [CI] | NE [NE−NE] | 5.0 [0.7−5.7] |
| Best overall response | ||
| CR, n (%) | 0 | 0 |
| PR, n (%) | 2 (25) | 0 |
| SD, n (%) | 4 (50) | 4 (40) |
| Non-CR/non-PD,an (%) | 2 (25) | 2 (20) |
| PD, n (%) | 0 | 0 |
| Not evaluable,bn (%) | 0 | 4 (40) |
| ORR,cn (%) | 2 (25) | 0 |
| DCR,dn (%) | 6 (75) | 4 (40) |
a
Patients who had no target lesion, without unequivocal CR or PD.
b
Patients died before tumor assessment or did not meet SD criteria.
c
ORR = CR + PR.
d
DCR = CR + PR + SD.
CR, complete response; DCR, disease control rate; NE, not estimable; ORR, partial response; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.